Investigational New Drugs

, Volume 31, Issue 2, pp 363–369 | Cite as

Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET

  • Jeffrey R. InfanteEmail author
  • Terence Rugg
  • Michael Gordon
  • Isabelle Rooney
  • Lee Rosen
  • Karin Zeh
  • Raymond Liu
  • Howard A. Burris
  • Ramesh K. Ramanathan


Purpose SGX523 is an orally bio-available, ATP competitive, small molecule inhibitor of MET, binding the kinase domain active site in a novel mode. Two phase 1, open-label, dose-escalation studies of SGX523 were conducted to evaluate both interrupted and continuous dosing schedules. Methods Thirty-six patients per study were planned to be enrolled. The first study explored a 21-day cycle with SGX523 administered on an intermittent schedule at a starting dose of 60 mg PO BID for 14 days followed by 7 days of rest. The second protocol explored a continuous 28-day dosing schedule with SGX523 administered at a starting dose of 20 mg PO BID for 28 days without rest. Results A total of 10 patients were enrolled, 2 on the intermittent dosing protocol and 8 on the continuous dosing protocol. All 6 patients that received daily doses of ≥ 80 mg developed unexpected renal failure manifested by an early rise of serum blood urea nitrogen and creatinine. Human PK analysis revealed the formation of two insoluble metabolites at levels not seen in the rat or dog preclinical toxicology studies. Subsequent primate toxicology and toxicokinetic evaluation replicated human findings, and histological examination of the monkey kidneys revealed the formation of crystals both within the renal tubules and within giant cell macrophages. Conclusion Two-species toxicology studies of SGX523 did not predict the occurrence of renal toxicity in the human. Subsequent primate toxicology studies suggest the cause of the renal failure seen in humans was a crystal nephropathy secondary to insoluble metabolites. SGX523 is no longer in clinical development.


MET inhibitor Crystal nephropathy Phase 1 study RTK inhibitors 


Conflicts of Interest

Terence Rugg, Isabelle Rooney, Raymond Liu: Full time employment by sponsor.

All other investigators have no other conflict.

Study was fully sponsored by SGX Pharmaceuticals.

Supplementary material

10637_2012_9823_MOESM1_ESM.pdf (16 kb)
Esm 1 Structure of SGX523 (PDF 16 kb)


  1. 1.
    Schmidt L, Junker K, Weirich G, Glenn G, Choyke P, Lubensky I et al (1998) Two North American Families with Hereditary Papillary Renal Carcinoma and Identical Novel Mutations in the MET Proto-Oncogene. Cancer Res 58(8):1719–1722PubMedGoogle Scholar
  2. 2.
    Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16(1):68–73PubMedCrossRefGoogle Scholar
  3. 3.
    Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio PM et al (1992) Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genetics and Cytogenetics 64(2):170–173PubMedCrossRefGoogle Scholar
  4. 4.
    Okada K, Sugihara H, Bamba M, Bamba T, Hattori T (2000) Sequential numerical changes of chromosomes 7 and 18 in diffuse-type stomach cancer cell lines: combined comparative genomic hybridization, fluorescence in situ hybridization, and ploidy analyses. Cancer Genetics and Cytogenetics 118(2):99–107PubMedCrossRefGoogle Scholar
  5. 5.
    Kovacs G (1993) Molecular cytogenetics of renal cell tumors. Adv Cancer Res 62:89–124PubMedCrossRefGoogle Scholar
  6. 6.
    Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D et al (2004) Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 95(10):803–809PubMedCrossRefGoogle Scholar
  7. 7.
    Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A (1996) Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 88(10):3998–4004PubMedGoogle Scholar
  8. 8.
    Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA et al (1997) Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57(23):5391–5398PubMedGoogle Scholar
  9. 9.
    Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY et al (2009) SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Molecular Cancer Therapeutics 8(12):3181–90PubMedCrossRefGoogle Scholar
  10. 10.
    Declaration of Helsinki. Ethical principles for medical research involving human subjects World Medical Association 1964.Google Scholar
  11. 11.
    Burley S (2009) SGX523 is an exquisitely selective ATP-competitive inhibitor of MET receptor tyrosine kinase. New York Academy of Sciences SymposiumGoogle Scholar
  12. 12.
    Diamond S, Boer J, Maduskuie TP, Falahatpisheh N, Li Y (2010) Yeleswaram S species-specific metabolism of SGX523 by Aldehyde Oxidase and the toxicological implications. Drug Metabolism and Disposition 38(8):1277–1285PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jeffrey R. Infante
    • 1
    Email author
  • Terence Rugg
    • 2
  • Michael Gordon
    • 3
  • Isabelle Rooney
    • 2
  • Lee Rosen
    • 4
  • Karin Zeh
    • 5
  • Raymond Liu
    • 2
  • Howard A. Burris
    • 1
  • Ramesh K. Ramanathan
    • 6
  1. 1.Sarah Canon Research InstituteNashvilleUSA
  2. 2.SGX PharmaceuticalsSan DiegoUSA
  3. 3.Premiere OncologyScottsdaleUSA
  4. 4.TGEN Clinical Research Service at Scottsdale Clinical Research InstituteScottsdaleUSA
  5. 5.Santaris Pharma A/SHoersholmDenmark
  6. 6.Premiere OncologySanta MonicaUSA

Personalised recommendations